EP0283801A3
(en)
*
|
1987-03-27 |
1990-05-30 |
Abbott Laboratories |
Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
|
US5236899A
(en)
*
|
1987-11-16 |
1993-08-17 |
Merck & Co., Inc. |
6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
|
US6007840A
(en)
*
|
1988-09-16 |
1999-12-28 |
Novartis Ag |
Pharmaceutical compositions comprising cyclosporins
|
KR0148748B1
(ko)
*
|
1988-09-16 |
1998-08-17 |
장 크라메르, 한스 루돌프 하우스 |
사이클로스포린을 함유하는 약학조성물
|
BE1003009A5
(fr)
*
|
1989-02-09 |
1991-10-22 |
Sandoz Sa |
Nouvelles compositions pharmaceutiques a base de cyclosporines.
|
US5540931A
(en)
*
|
1989-03-03 |
1996-07-30 |
Charles W. Hewitt |
Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
|
GB8916901D0
(en)
*
|
1989-07-24 |
1989-09-06 |
Sandoz Ltd |
Improvements in or relating to organic compounds
|
US5122511A
(en)
*
|
1990-02-27 |
1992-06-16 |
Merck & Co., Inc. |
Immunosuppressive cyclosporin analogs with modified amino acids at position-8
|
US6262022B1
(en)
|
1992-06-25 |
2001-07-17 |
Novartis Ag |
Pharmaceutical compositions containing cyclosporin as the active agent
|
GB9204466D0
(en)
*
|
1992-03-02 |
1992-04-15 |
Sandoz Ltd |
Improvements in or relating to organic compounds
|
GB9208712D0
(en)
*
|
1992-04-22 |
1992-06-10 |
Sandoz Ltd |
Pharmaceutical compositions containing cyclosporin derivates
|
WO1993023010A1
(en)
|
1992-05-13 |
1993-11-25 |
Sandoz Ltd. |
Ophthalmic compositions containing a cyclosporin
|
SK278290B6
(en)
*
|
1992-09-07 |
1996-08-07 |
Milan Stuchlik |
Medicaments with n-methylated cyclic undecapeptides
|
ES2168271T3
(es)
|
1992-09-25 |
2002-06-16 |
Novartis Ag |
Composiciones farmaceuticas que contienen ciclosporinas.
|
US20020099067A1
(en)
*
|
1993-07-08 |
2002-07-25 |
Ulrich Posanski |
Pharmaceutical compositions for sparingly soluble therapeutic agents
|
US6187547B1
(en)
|
1993-09-08 |
2001-02-13 |
Novartis Ag |
Assay kit
|
GB9318612D0
(en)
*
|
1993-09-08 |
1993-10-27 |
Sandoz Ltd |
An assay
|
US6334997B1
(en)
*
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
KR20040068613A
(ko)
*
|
1994-03-25 |
2004-07-31 |
이소테크니카 인코포레이티드 |
중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
|
EP0789580B1
(de)
|
1994-11-03 |
2002-06-05 |
Novartis AG |
Neue zubereitungsformen des cyclosporins zur oralen applikation mit einfacher zusammensetzung und hoher bioverfügbarkeit und verfahren zu deren herstellung
|
GR1002687B
(el)
*
|
1995-04-17 |
1997-05-06 |
Novartis Ag (Novartis Sa) (Novartis Inc.) |
Διαδικασια παραγωγης.
|
US6395770B1
(en)
|
1995-10-26 |
2002-05-28 |
Baker Norton Pharmaceuticals, Inc. |
Method and compositions for administering taxanes orally to human patients
|
US6245805B1
(en)
*
|
1995-10-26 |
2001-06-12 |
Baker Norton Pharmaceuticals, Inc. |
Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
|
DE19544507B4
(de)
|
1995-11-29 |
2007-11-15 |
Novartis Ag |
Cyclosporin enthaltende Präparate
|
GB9601120D0
(en)
*
|
1996-01-19 |
1996-03-20 |
Sandoz Ltd |
Organic compounds
|
ES2229473T3
(es)
|
1997-01-30 |
2005-04-16 |
Novartis Ag |
Composiciones farmaceuticas sin aceite que contienen ciclosporina a.
|
US20030220234A1
(en)
*
|
1998-11-02 |
2003-11-27 |
Selvaraj Naicker |
Deuterated cyclosporine analogs and their use as immunodulating agents
|
ATE314388T1
(de)
*
|
1997-10-08 |
2006-01-15 |
Isotechnika Inc |
Deuterierte und undeuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agentien
|
US6201165B1
(en)
|
1997-10-16 |
2001-03-13 |
Board Of Regents, University Of Texas System |
Transgenic animal models for cardiac hypertrophy and methods of use thereof
|
EP1091975B1
(fr)
|
1998-07-01 |
2005-12-14 |
Debiopharm S.A. |
Nouvelle cyclosporine ayant un profil d'activite ameliore
|
NZ512599A
(en)
|
1998-12-30 |
2003-10-31 |
Dexcel Ltd |
Formulation for cyclosporin administration featuring a hydrophilic solvent and a surfactant with a HLB of less than 5
|
US6255280B1
(en)
*
|
1999-04-08 |
2001-07-03 |
University Of Kentucky Research Foundation |
Protection against traumatic brain injury
|
US7732404B2
(en)
|
1999-12-30 |
2010-06-08 |
Dexcel Ltd |
Pro-nanodispersion for the delivery of cyclosporin
|
US6784156B2
(en)
|
2001-03-05 |
2004-08-31 |
Enanta Pharmaceuticals, Inc. |
Cyclosporins for the treatment of respiratory diseases
|
GB0113663D0
(en)
*
|
2001-06-05 |
2001-07-25 |
Novartis Ag |
Use of organic compounds
|
US6809077B2
(en)
*
|
2001-10-12 |
2004-10-26 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogs for the treatment of autoimmune diseases
|
US20030087813A1
(en)
*
|
2001-10-12 |
2003-05-08 |
Or Yat Sun |
Cyclosporin analogs for the treatment of lung diseases
|
KR100992850B1
(ko)
*
|
2001-10-19 |
2010-11-09 |
이소테크니카 인코포레이티드 |
시클로스포린 유사체 혼합물 및 면역조절제로서 이들의 용도
|
AU2007221839B2
(en)
*
|
2001-10-19 |
2011-05-12 |
Aurinia Pharmaceuticals Inc. |
Synthesis of cyclosporin analogs
|
JP2005506990A
(ja)
*
|
2001-10-19 |
2005-03-10 |
アイソテクニカ インコーポレーテッド |
新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート
|
ES2326040T3
(es)
*
|
2001-10-19 |
2009-09-29 |
Isotechnika Inc. |
Sintesis de analogos de ciclosporina.
|
US7012065B2
(en)
|
2003-02-07 |
2006-03-14 |
Enanta Pharmaceuticals, Inc. |
Cyclosporins for the treatment of immune disorders
|
WO2004082629A2
(en)
*
|
2003-03-17 |
2004-09-30 |
Albany Molecular Research, Inc. |
Novel cyclosporins
|
TW200505946A
(en)
*
|
2003-04-08 |
2005-02-16 |
Hoffmann La Roche |
Process for preparation of cyclosporin a analog
|
CA2561907A1
(en)
*
|
2004-04-08 |
2005-10-20 |
Applied Research Systems Ars Holding N.V. |
Composition comprising a jnk inhibitor and cyclosporin
|
US20060014677A1
(en)
*
|
2004-07-19 |
2006-01-19 |
Isotechnika International Inc. |
Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
|
US7378391B2
(en)
*
|
2004-09-29 |
2008-05-27 |
Amr Technology, Inc. |
Cyclosporin alkyne analogues and their pharmaceutical uses
|
WO2006039164A2
(en)
*
|
2004-09-29 |
2006-04-13 |
Amr Technology, Inc. |
Novel cyclosporin analogues and their pharmaceutical uses
|
WO2006041631A2
(en)
*
|
2004-10-06 |
2006-04-20 |
Amr Technology, Inc. |
Novel cyclosporin alkynes and their utility as pharmaceutical agents
|
MX2007007262A
(es)
*
|
2004-12-17 |
2007-10-19 |
Isotechnika Inc |
Metabolitos de analogos de ciclosporina.
|
US7696165B2
(en)
*
|
2006-03-28 |
2010-04-13 |
Albany Molecular Research, Inc. |
Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
|
US7696166B2
(en)
*
|
2006-03-28 |
2010-04-13 |
Albany Molecular Research, Inc. |
Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
|
WO2008036244A1
(en)
*
|
2006-09-18 |
2008-03-27 |
The Burham Institute For Medical Research |
Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands
|
CA2674296C
(en)
*
|
2007-01-04 |
2015-11-24 |
Debiopharm Sa |
Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
|
TW200932240A
(en)
|
2007-10-25 |
2009-08-01 |
Astellas Pharma Inc |
Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
|
EP2307446A4
(en)
*
|
2008-07-30 |
2012-11-07 |
Isotechnika Pharma Inc |
NON-IMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGOUS MOLECULES
|
KR20110071014A
(ko)
|
2008-10-17 |
2011-06-27 |
위스콘신 얼럼나이 리서어치 화운데이션 |
생물학적으로 활성인 알파-베타 펩티드의 제조 방법
|
JP5780969B2
(ja)
*
|
2008-12-31 |
2015-09-16 |
サイネクシス,インコーポレーテッド |
シクロスポリンaの誘導体
|
WO2010088573A1
(en)
*
|
2009-01-30 |
2010-08-05 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogues for preventing or treating hepatitis c infection
|
US8481483B2
(en)
*
|
2009-02-19 |
2013-07-09 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogues
|
US8349312B2
(en)
*
|
2009-07-09 |
2013-01-08 |
Enanta Pharmaceuticals, Inc. |
Proline substituted cyclosporin analogues
|
US8685917B2
(en)
*
|
2009-07-09 |
2014-04-01 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogues
|
US8367053B2
(en)
*
|
2009-07-09 |
2013-02-05 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogues
|
DE102009037551A1
(de)
|
2009-08-17 |
2011-02-24 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Cyclosporinderivate
|
US8623814B2
(en)
*
|
2010-02-23 |
2014-01-07 |
Enanta Pharmaceuticals, Inc. |
Antiviral agents
|
WO2011141891A1
(en)
|
2010-05-12 |
2011-11-17 |
Debio Recherche Pharmaceutique S.A. |
Use of cycloundecadepsipeptide compounds
|
RU2630690C9
(ru)
|
2010-12-15 |
2017-12-28 |
КонтраВир Фармасьютикалз, Инк. |
МОЛЕКУЛЫ АНАЛОГОВ ЦИКЛОСПОРИНА, МОДИФИЦИРОВАННЫЕ ПО 1 и 3 АМИНОКИСЛОТЕ
|
WO2012145427A1
(en)
|
2011-04-18 |
2012-10-26 |
The Trustees Of Columbia University In The City Of New York |
Methods to treat cancer using cyclosporine and cyclosporine derivatives
|
EP2900684A2
(en)
|
2012-09-29 |
2015-08-05 |
Novartis AG |
Cyclic peptides and use as medicines
|
WO2014085623A1
(en)
|
2012-11-28 |
2014-06-05 |
Enanta Pharmaceuticals, Inc. |
Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
|
JP2016538317A
(ja)
|
2013-08-26 |
2016-12-08 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
C型肝炎を防止または治療するための新規シクロスポリン類似体
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
CU24481B1
(es)
|
2014-03-14 |
2020-03-04 |
Immutep Sas |
Moléculas de anticuerpo que se unen a lag-3
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
CR20170143A
(es)
|
2014-10-14 |
2017-06-19 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
WO2016073480A1
(en)
|
2014-11-03 |
2016-05-12 |
Enanta Pharmaceuticals, Inc. |
Novel cyclosporin analogues for preventing or treating hepatitis c infection
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
TN2017000375A1
(en)
|
2015-03-10 |
2019-01-16 |
Aduro Biotech Inc |
Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
WO2017019896A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
CA2996064C
(en)
|
2015-08-18 |
2024-02-13 |
Novation Pharmaceuticals Inc. |
Benzopyran derivatives and uses thereof
|
SG11201803520PA
(en)
|
2015-11-03 |
2018-05-30 |
Janssen Biotech Inc |
Antibodies specifically binding pd-1 and their uses
|
AU2016369537B2
(en)
|
2015-12-17 |
2024-03-14 |
Novartis Ag |
Antibody molecules to PD-1 and uses thereof
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
SG11201912473PA
(en)
|
2017-06-22 |
2020-01-30 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
CN114208781B
(zh)
*
|
2022-01-20 |
2022-12-20 |
河南农业大学 |
一种抑制草地贪夜蛾龄期的方法及其应用
|